

# CITATION REPORT

List of articles citing

**Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders**

**DOI: 10.1111/j.1365-2036.2012.05011.x**

**Alimentary Pharmacology and Therapeutics, 2012, 35, 745-67.**

**Source:** <https://exaly.com/paper-pdf/54467547/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
225	Chronic constipation: new diagnostic and treatment approaches. <b>2012</b> , 5, 233-47		28
224	Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. <b>2012</b> , 8, 1327-35		27
223	Recent advances in the management of difficult constipation. <b>2012</b> , 14, 306-12		2
222	Commentary: towards a cardiac safe prokinetic. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1243-4	6.1	5
221	Constella(EU)-Linzess(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs. <b>2013</b> , 5, 291-300		10
220	Treatment of opioid-induced constipation: focus on the peripheral $\mu$ opioid receptor antagonist methylnaltrexone. <b>2013</b> , 73, 1297-306		20
219	Emerging pharmacological therapy for functional dyspepsia. <b>2013</b> , 6, 352-6		6
218	Prucalopride: a review of its use in the management of chronic constipation. <b>2013</b> , 73, 1935-50		22
217	Chronic constipation: a critical review. <b>2013</b> , 45, 886-93		66
216	New treatments for IBS. <b>2013</b> , 10, 13-23		25
215	An in vitro investigation of the cardiovascular effects of the 5-HT <sub>4</sub> receptor selective agonists, velusetrag and TD-8954. <b>2013</b> , 58, 150-6		21
214	Elobixibat for the treatment of constipation. <b>2013</b> , 22, 277-84		27
213	Effects of the 5-HT <sub>4</sub> receptor agonist, cisapride, on neuronally evoked responses in human bladder, urethra, and ileum. <b>2013</b> , 176, 70-7		9
212	Pharmacological profile of engineered 5-HT <sub>4</sub> receptors and identification of 5-HT <sub>4</sub> receptor-biased ligands. <b>2013</b> , 1511, 65-72		7
211	Diabetic gastroparesis: recent insights into pathophysiology and implications for management. <b>2013</b> , 7, 127-39		17
210	Effect of DA-9701, a novel prokinetic agent, on stress-induced delayed gastric emptying and hormonal changes in rats. <b>2013</b> , 25, 254-9, e166		23
209	Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. <b>2013</b> , 9, 403-21		11

208	Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. <b>2013</b> , 10, 473-86		537
207	Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. <b>2013</b> , 4, 50		13
206	Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. <b>2013</b> , 1, 7-20		23
205	Emerging treatments for chronic constipation. <b>2013</b> , 18, 365-73		8
204	Functional constipation in childhood: current pharmacotherapy and future perspectives. <b>2013</b> , 14, 41-51		21
203	Irritable bowel syndrome pharmacotherapy. <b>2013</b> , 105-129		
202	Drug development for the irritable bowel syndrome: current challenges and future perspectives. <b>2013</b> , 4, 7		24
201	Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. <b>2014</b> , 20, 2412-9		59
200	Gastrointestinal Drugs. <b>2014</b> , 36, 539-560		1
199	Therapeutic options for functional dyspepsia. <b>2014</b> , 32, 230-4		22
198	Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. <b>2014</b> , 10, 293-305		13
197	Prucalopride is no more effective than placebo for children with functional constipation. <i>Gastroenterology</i> , <b>2014</b> , 147, 1285-95.e1	13.3	54
196	Systematic review with meta-analysis: highly selective 5-HT <sub>4</sub> agonists (prucalopride, velusetrag or naronapride) in chronic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 239-53	6.1	100
195	Novel pharmacological therapies for management of chronic constipation. <b>2014</b> , 48, 21-8		18
194	Emerging drugs for the treatment of gastroparesis. <b>2014</b> , 19, 261-79		10
193	Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments. <b>2014</b> , 20, 2499-514		31
192	Chronic constipation and treatment options (Review). <b>2014</b> , 9, 3-8		15
191	Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. <b>2014</b> , 18, 613-21		71

190	Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case series. <b>2014</b> , 8, 34	15
189	Treatment of abdominal pain in irritable bowel syndrome. <b>2014</b> , 49, 1193-205	38
188	Acute and subchronic toxicities of QX100626, a 5-HT <sub>4</sub> receptor agonist, in rodents and Beagle dogs. <b>2014</b> , 70, 379-91	1
187	Novel therapeutic agents in neurogastroenterology: advances in the past year. <b>2014</b> , 26, 1070-8	14
186	Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity. <b>2014</b> , 15, 14	14
185	Phase II drugs under clinical investigation for the treatment of chronic constipation. <b>2014</b> , 23, 1485-97	16
184	Treatment for constipation: new and old pharmacological strategies. <b>2014</b> , 26, 749-63	7
183	Synthesis and structure-activity relationship studies in serotonin 5-HT <sub>4</sub> receptor ligands based on a benzo[de][2,6]naphthridine scaffold. <b>2014</b> , 82, 36-46	12
182	Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. <b>2014</b> , 8, 435-43	31
181	Current developments in pharmacological therapeutics for chronic constipation. <b>2015</b> , 5, 300-9	37
180	The use of antidepressants and the risk of chronic atrial fibrillation. <b>2015</b> , 55, 423-30	6
179	The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. <b>2015</b> , 27, 1629-37	22
178	Prokinetics in the Management of Functional Gastrointestinal Disorders. <b>2015</b> , 21, 330-6	37
177	Optimal management of constipation associated with irritable bowel syndrome. <b>2015</b> , 11, 691-703	10
176	Electroacupuncture versus Moxibustion for Irritable Bowel Syndrome: A Randomized, Parallel-Controlled Trial. <b>2015</b> , 2015, 361786	14
175	Ghrelin Agonists as Emerging Prokinetic Agents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2326-33	3
174	Emerging drugs for functional dyspepsia. <b>2015</b> , 20, 221-33	28
173	Current Concepts in the Treatment of Multiple System Atrophy. <b>2015</b> , 2, 6-16	15

172	Efficacy and safety of prucalopride in adults and children with chronic constipation. <b>2015</b> , 16, 407-16	15
171	Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials. <b>2015</b> , 24, 769-79	22
170	A randomized trial of 5-hydroxytryptamine <sub>4</sub> -receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 701-8.e1	6.9 24
169	Safety of medication options for treating pediatric esophagitis. <b>2015</b> , 14, 1087-96	2
168	Therapeutic options in oesophageal dysphagia. <b>2015</b> , 12, 332-41	21
167	The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. <b>2015</b> , 16, 2449-64	38
166	Current and Emerging Medical Therapies for Gastroparesis. <b>2015</b> , 13, 452-72	5
165	The use of biomarkers in human pharmacology (Phase I) studies. <b>2015</b> , 55, 55-74	35
164	Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach. <b>2016</b> , 10, 3125-3132	3
163	Effect of DA-9701 on the Normal Motility and Clonidine-induced Hypomotility of the Gastric Antrum in Rats. <b>2016</b> , 22, 304-9	4
162	Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials. <b>2016</b> , 22, 412-22	35
161	Randomized clinical trial: a controlled pilot trial of the 5-HT <sub>4</sub> receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. <b>2016</b> , 28, 487-97	24
160	Velusetrag for the treatment of chronic constipation. <b>2016</b> , 25, 985-90	7
159	Constipation: Pathophysiology and Current Therapeutic Approaches. <b>2017</b> , 239, 59-74	58
158	Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. <b>2017</b> , 239, 319-342	54
157	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <b>2016</b> , 61, 2357-2372	52
156	Synergistic effect between 5-HT <sub>4</sub> receptor agonist and phosphodiesterase 4-inhibitor in releasing acetylcholine in pig gastric circular muscle in vitro. <b>2016</b> , 781, 76-82	7
155	Safety of treatment for gastroparesis. <b>2016</b> , 15, 937-45	5

154	Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. <b>2016</b> , 61, 2655-65	17
153	Management of refractory typical GERD symptoms. <b>2016</b> , 13, 281-94	55
152	Synthesis and evaluation of novel serotonin 4 receptor radiotracers for single photon emission computed tomography. <b>2016</b> , 116, 90-101	5
151	The Mexican consensus on irritable bowel syndrome. <b>2016</b> , 81, 149-167	
150	Cisapride, a selective serotonin 5-HT <sub>4</sub> -receptor agonist, inhibits voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells. <b>2016</b> , 478, 1423-8	3
149	Activation of islet 5-HT <sub>4</sub> receptor regulates glycemic control through promoting insulin secretion. <b>2016</b> , 789, 354-361	7
148	Prucalopride exerts neuroprotection in human enteric neurons. <b>2016</b> , 310, G768-75	23
147	A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers. <b>2016</b> , 38, 2106-15	9
146	Management of autonomic dysfunction in Parkinson's disease. 93-110	2
145	Modern Management of Irritable Bowel Syndrome: More Than Motility. <b>2016</b> , 34, 566-73	13
144	Functional Dyspepsia and Gastroparesis. <b>2016</b> , 34, 491-9	38
143	Advancing treatment options for chronic idiopathic constipation. <b>2016</b> , 17, 501-11	12
142	Prucalopride: A Review in Chronic Idiopathic Constipation. <b>2016</b> , 76, 99-110	11
141	The Mexican consensus on irritable bowel syndrome. <b>2016</b> , 81, 149-67	14
140	Editorial: serotonin and irritable bowel syndrome--reconciling pharmacological effects with basic biology. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 644-6	6.1 2
139	Being constipated: A bad omen for your cardiovascular system?. <b>2016</b> , 245, 240-1	3
138	Mexican consensus on dyspepsia. <b>2017</b> , 82, 309-327	10
137	Modulating 5-HT and 5-HT receptors in Alzheimer's disease treatment. <b>2017</b> , 9, 781-795	24

136	Pharmacological and Clinical Treatment of Irritable Bowel Syndrome. <b>2017</b> , 43-61	
135	Pediatric Chronic Intestinal Pseudo-obstruction. <b>2017</b> , 273-290	1
134	The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. <b>2017</b> , 11, 139-148	20
133	Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl-Induced Cirrhotic Rats. <b>2017</b> , 62, 2801-2811	4
132	Prokinetics in the Management of Functional Gastrointestinal Disorders. <b>2017</b> , 19, 53	17
131	Weikangning therapy in functional dyspepsia and the protective role of Nrf2. <b>2017</b> , 14, 2885-2894	2
130	Gastroparesis: Medical and Therapeutic Advances. <b>2017</b> , 62, 2231-2240	30
129	Mexican consensus on dyspepsia. <b>2017</b> , 82, 309-327	
128	The safety of available treatments for chronic constipation. <b>2017</b> , 16, 1243-1253	14
127	4-Substituted and 1,4-Disubstituted Piperidines. <b>2017</b> , 147-221	1
126	Existing and emerging therapies for managing constipation and diarrhea. <b>2017</b> , 37, 158-166	21
125	An update on prucalopride in the treatment of chronic constipation. <b>2017</b> , 10, 877-887	38
124	Gastroprotective and gastric motility benefits of AD-lico/Healthy Gut Extract. <b>2017</b> , 21, 255-262	5
123	Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. <b>2017</b> , 17, 83	36
122	Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. <b>2017</b> , 19, 145	27
121	Prokinetic effects of a new 5-HT agonist, YKP10811, on gastric motility in dogs. <b>2017</b> , 32, 625-630	4
120	Colonic N-methyl-d-aspartate receptor contributes to visceral hypersensitivity in irritable bowel syndrome. <b>2017</b> , 32, 828-836	13
119	Increased expression of tight junction protein occludin is associated with the protective effect of mosapride against aspirin-induced gastric injury. <b>2018</b> , 15, 1626-1632	6

118	Quantum mechanics implementation in drug-design workflows: does it really help?. <b>2017</b> , 11, 2551-2564	17
117	Prokinetic effects of LD02GIFRO on functional gastrointestinal disorder in rats. <b>2017</b> , 13, 2043-2049	2
116	New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. <b>2017</b> , 23, 6593-6627	25
115	Intestinal Involvement in Systemic Sclerosis: A Clinical Review. <b>2018</b> , 63, 834-844	24
114	Cardiotoxicity of Drugs. <b>2018</b> , 93-110	3
113	The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT receptor agonist, DSP-6952. <b>2018</b> , 826, 96-105	6
112	Acupuncture for patients with chronic functional constipation: A randomized controlled trial. <b>2018</b> , 30, e13307	18
111	Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. <b>2018</b> , 30, e13302	36
110	Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders. <b>2018</b> , 132, 1-6	48
109	New therapies in Irritable Bowel Syndrome: what works and when. <b>2018</b> , 34, 50-56	4
108	Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist. <b>2018</b> , 364, 156-169	2
107	The novel, potent and highly selective 5-HT receptor agonist YH12852 significantly improves both upper and lower gastrointestinal motility. <b>2018</b> , 175, 485-500	11
106	Gastroparesis: pharmacotherapy and cardiac risk. <b>2018</b> , 53, 513-518	8
105	Irritable bowel syndrome: the clinical approach. <b>2018</b> , 60, 213-222	32
104	Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCS) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies. <b>2018</b> , 19, 3791-3808	5
103	New developments in the treatment of gastroparesis and functional dyspepsia. <b>2018</b> , 43, 111-117	52
102	Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects. <b>2018</b> , 16, 489-510	9
101	Diabetic gastroparesis: current challenges and future prospects. <b>2018</b> , 11, 347-363	21



100	Safety and Efficacy of in Functional Dyspepsia: A Randomized, Double-Blinded, Placebo-Controlled Study. <b>2018</b> , 2018, 4813601		11
99	Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. <b>2018</b> , 11, 119-134		35
98	New treatments and therapeutic targets for IBS and other functional bowel disorders. <b>2018</b> , 15, 589-605		68
97	Recent advances in pharmacological research on the management of irritable bowel syndrome. <b>2018</b> , 41, 955-966		15
96	Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion. <b>2018</b> , 23, 775-785.e5		136
95	Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. <b>2019</b> , 180, 690-706		17
94	Second Asian Consensus on Irritable Bowel Syndrome. <b>2019</b> , 25, 343-362		31
93	Drugs under development for the treatment of functional dyspepsia and related disorders. <b>2019</b> , 28, 871-889		11
92	Gastroparesis: a turning point in understanding and treatment. <b>2019</b> , 68, 2238-2250		71
91	Reprint of: Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders. <b>2019</b> , 140, 115-120		16
90	Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study. <b>2019</b> , 42, 1179-1190		16
89	Concise Review: Cellular and Molecular Mechanisms of Postnatal Injury-Induced Enteric Neurogenesis. <b>2019</b> , 37, 1136-1143		8
88	Use of prucalopride in adults with chronic idiopathic constipation. <b>2019</b> , 12, 579-589		15
87	Prokinetic effects of spinal cord stimulation and its autonomic mechanisms in dogs. <b>2019</b> , 31, e13596		1
86	Review article: treatment options for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1134-1172	6.1	51
85	The Unfulfilled Promise of Prokinetics for Functional Dyspepsia/Postprandial Distress Syndrome. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 204-206	0.7	12
84	Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1265-1274	0.7	84
83	Implications of Pharmacogenomics to the Management of IBS. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 584-594	6.9	3

82	Tegaserod for the Treatment of Irritable Bowel Syndrome. <b>2020</b> , 19, 342-369		8
81	A 3-Part Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DSP-6952 in Healthy Japanese Subjects and Those With B Spontaneous Bowel Movements per Week. <i>Clinical Pharmacology in Drug Development</i> , <b>2020</b> , 9, 353-365	2,3	3
80	Novel aspects of enteric serotonergic signaling in health and brain-gut disease. <b>2020</b> , 318, G130-G143		21
79	Current and emerging therapeutic options for the management of functional dyspepsia. <b>2020</b> , 21, 365-376		7
78	Targeting the 5-HT system: Potential side effects. <b>2020</b> , 179, 108233		11
77	Functional Dyspepsia: Diagnostic and Therapeutic Approaches. <b>2020</b> , 80, 1319-1336		13
76	Efficacy of massage therapy for postprandial distress syndrome: A protocol for systematic review and meta-analysis. <b>2020</b> , 99, e23473		0
75	The Enteric Nervous System and Its Emerging Role as a Therapeutic Target. <b>2020</b> , 2020, 8024171		11
74	Pharmacologic treatment of GERD: Where we are now, and where are we going?. <b>2020</b> , 1482, 193-212		7
73	Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis. <b>2020</b> , 9,		1
72	Towards the quantum-enabled technologies for development of drugs or delivery systems. <b>2020</b> , 324, 260-279		12
71	In silico systems for predicting chemical-induced side effects using known and potential chemical protein interactions, enabling mechanism estimation. <b>2020</b> , 45, 137-149		3
70	Thorough QT/QTc Study Shows That a Novel 5-HT Receptor Partial Agonist Minesapride Has No Effect on QT Prolongation. <i>Clinical Pharmacology in Drug Development</i> , <b>2020</b> , 9, 938-951	2,3	4
69	Managing autonomic dysfunction in Parkinson's disease: a review of emerging drugs. <b>2020</b> , 25, 37-47		4
68	IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. <i>Gastroenterology</i> , <b>2020</b> , 158, 2093-2103	1,3	20
67	A Novel Approach in Spinal Cord Stimulation for Enhancing Gastric Motility: A Preliminary Study on Canines. <b>2020</b> , 26, 147-159		4
66	Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity. <b>2020</b> , 9, e1901656		12
65	Efficacy and Safety of 5-HT <sub>4</sub> Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 538-548.e8	6,9	9

64	YH12852, a Potent and Selective Receptor Agonist of 5-hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation. <b>2021</b> , 14, 625-634	2
63	Prokinetic actions of luminally acting 5-HT receptor agonists. <b>2021</b> , 33, e14026	3
62	The role of serotonin in the control of esophageal sensitivity assessed by multimodal stimulation in health. <b>2021</b> , 33, e14057	1
61	The Physiology and Pharmacology of Diabetic Gastropathy Management. <b>2021</b> ,	
60	A vision of the future for gastroparesis. <b>2021</b> , 527-538	
59	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <b>2021</b> , 33, e14070	2
58	The effect of prucalopride on gastric sensorimotor function and satiation in healthy volunteers. <b>2021</b> , 33, e14083	2
57	Toward a broader view of mechanisms of drug cardiotoxicity. <b>2021</b> , 2, 100216	7
56	Colonic 5-HT receptors are targets for novel prokinetic drugs. <b>2021</b> , 33, e14125	2
55	Chemical Aspects of Human and Environmental Overload with Fluorine. <b>2021</b> , 121, 4678-4742	49
54	Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. <b>2021</b> , 16, 25-35	1
53	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <b>2021</b> , 9, 307-331	20
52	Non-Achalasia Esophageal Motility Abnormalities. <b>2021</b> , 265-277	
51	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. <b>2021</b> , 9, 287-306	8
50	Management of Ineffective Esophageal Hypomotility. <b>2021</b> , 12, 638915	2
49	Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9 1
48	Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety. <b>2021</b> , 17, 601-615	2
47	Editorial: finding the ideal prokinetic for gastroparesis-we are not there yet. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 210-211	6.1 0

46	A population pharmacokinetic-pharmacodynamic model of YH12852, a highly selective 5-hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation. <b>2021</b> , 10, 902-913	2
45	Gastrointestinal manifestations of systemic sclerosis: An updated review. <b>2021</b> , 9, 6201-6217	1
44	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. <b>2021</b> , 33, e14237	2
43	New Developments in Prokinetic Therapy for Gastric Motility Disorders. <b>2021</b> , 12, 711500	8
42	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <b>2021</b> , 33, e14238	4
41	Tryptophan-derived serotonin-kynurenine balance in immune activation and intestinal inflammation. <b>2021</b> , 35, e21888	8
40	Transition-Metal-Free, Visible-Light-Mediated N-acylation: An Efficient Route to Amides in Water. <b>2020</b> , 9, 1032-1035	6
39	Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance. <b>2021</b> , 45, 115-124	11
38	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. <b>2021</b> , 73, 310-520	48
37	Newer agents for constipation: prucalopride. <b>2013</b> , 132-142	0
36	Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. <b>2014</b> , 20, 8898-909	22
35	Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation. <b>2014</b> , 20, 141-51	19
34	Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies. <b>2014</b> , 20, 458-68	19
33	Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer's Disease Treatment. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4 2
32	Safety/Efficacy of Prucalopride in Korean Patients with Chronic Constipation: Post-marketing Surveillance. <b>2021</b> , 78, 219-226	1
31	Intestinal Dysfunction in Parkinson's Disease. <b>2013</b> , 155-171	0
30	Chronic Constipation. <b>2014</b> , 41-65	
29	New Generation Laxatives. <i>Korean Journal of Medicine</i> , <b>2015</b> , 88, 9	0.5

28	Chronic Intestinal Pseudo-Obstruction in Childhood. <b>2016</b> , 269-280		
27	Approach to the Patient with Dyspepsia and Related Functional Gastrointestinal Complaints. 651-656		
26	The Pharmacological Management of Chronic Constipation and Faecal Incontinence. <b>2016</b> , 173-190		
25	Prokinetics in Treatment of Gastric Motility Disorders. <b>2017</b> , 245-258		
24	Reflux Inhibitors and Prokinetics. <b>2018</b> , 293-302		
23	Refractory Gastroesophageal Reflux Disease: A Management Update. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 765061	4.8	5
22	Pharmacology of Serotonin and Its Receptors. <b>2020</b> , 183-212		
21	Agent Clustering Strategy Based on Metabolic Flux Distribution and Transcriptome Expression for Novel Drug Development. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	
20	Upper Gastrointestinal Manifestations of Diabetes. <b>2021</b> , 269-279		
19	Intestinal Pseudo-Obstruction. <b>2022</b> , 313-325		
18	The Advantages and Disadvantages of Prokinetics. <i>Korean Journal of Medicine</i> , <b>2021</b> , 96, 478-483	0.5	
17	Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor.. <i>Clinical Pharmacology in Drug Development</i> , <b>2022</b> ,	2.3	0
16	TEGASEROD: WHAT'S OLD IS NEW AGAIN.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	0
15	Pharmacokinetics of DA-6886, A New 5-HT Receptor Agonist, in Rats.. <i>Pharmaceutics</i> , <b>2022</b> , 14,	6.4	
14	The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy.. <i>Molecules</i> , <b>2022</b> , 27,	4.8	7
13	Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117, S6-S13	0.7	1
12	Prucalopride for Treatment of Upper Gastrointestinal Symptoms in Children.. <i>Paediatric Drugs</i> , <b>2021</b> , 24, 73	4.2	1
11	Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 1218-1219	6.1	0

10	Management of scleroderma gastrointestinal disease: Lights and shadows.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 85-97	2.3	1
9	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , <b>2022</b> , 163, 118-136	13.3	2
8	Aspalathus linearis (Rooibos) and Agmatine May Act Synergistically to Beneficially Modulate Intestinal Tight Junction Integrity and Inflammatory Profile. <b>2022</b> , 15, 1097		0
7	YINDARA-4 Relieves Visceral Hypersensitivity in Irritable Bowel Syndrome Rats via Regulation of Gut Microbiota and Serotonin Levels. Publish Ahead of Print,		0
6	Gastroparesis and functional dyspepsia: spectrum of gastroduodenal neuromuscular disorders or unique entities?. <b>2022</b> ,		0
5	Trends in Gastroparesis Management. Publish Ahead of Print,		0
4	Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders.		0
3	Pediatric Intestinal Pseudo-Obstruction. <b>2022</b> , 333-353		0
2	Targeting the altered duodenal microenvironment in functional dyspepsia. <b>2023</b> , 70, 102363		0
1	Paracrine relationship between incretin hormones and endogenous 5-hydroxytryptamine in the small and large intestine.		0